Achema middle east

Agilent Technologies and Oxford Gene Technology Expand Microarray and Sequencing Partnership

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

The Future of Health and Wellbeing: A Market on the Rise

The health and wellbeing market has experienced significant growth...

Synthetic Drugs: A Growing Crisis or Signs of Improvement?

The landscape of drug usage has undergone significant changes...

Eli Lilly Becomes the First Drugmaker to Hit $1tn Valuation

Eli Lilly, the US pharma giant, has become the...
- Advertisement -

Agilent Technologies Inc. and Oxford Gene Technology today announced they have expanded an existing partnership into an exclusive agreement for Agilent to provide OGT with oligonucleotide microarrays and SureSelect target enrichment products for next-generation sequencing.

Mike Evans, chief executive of OGT, said: “We are delighted to have been able to broaden our supply partnership with Agilent to include the industry-leading SureSelect platform for our recently launched Genefficiency next-generation sequencing service. We are also pleased to extend our OEM supply agreement for oligonucleotide microarrays, building on the success of our comprehensive CytoSure product range for cytogenetics.”

“Agilent and OGT have a very close working relationship and we are excited to expand our collaboration to the SureSelect platform under our Certified Services Provider program,” said Robert Schueren, vice president and general manager of Agilent’s genomics business. “OGT’s bioinformatics capabilities add significant value to customers targeting specific areas of the genome with our SureSelect product line.”

Latest stories

Related stories

The Future of Health and Wellbeing: A Market on the Rise

The health and wellbeing market has experienced significant growth...

Synthetic Drugs: A Growing Crisis or Signs of Improvement?

The landscape of drug usage has undergone significant changes...

Eli Lilly Becomes the First Drugmaker to Hit $1tn Valuation

Eli Lilly, the US pharma giant, has become the...

400 Global Regulatory Manufacturing Approvals for Samsung Biologics

Samsung Biologics announced on November 26, 2025, that it has gone...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »